New platform aims to develop novel therapies for rare diseases

Updated: Feb 2 2023 1:25PM

New Delhi, Feb 2 (PTI) Researchers are working on a new platform that aims to develop several treatments, including gene and mRNA therapies, for three "rare" diseases which are estimated to affect about one million people in India.

The Myo-Mission anchored by Ashoka University, Sonipat in partnership with 18 institutions and 38 investigators across India, will enhance capabilities for carrying out future clinical trials for Duchene Muscular Dystrophy, GNE Myopathy and Limb-Girdle Muscular Dystrophy (LGMD).

All the three diseases either lead to muscular weakness or muscle wasting, and can cause permanent disability.

Press Trust Of India (PTI) is India's premier news agency, with a reach as vast as the Indian Railways'. It employs nearly 400 journalists and 500 stringers to cover almost every city and small town in India. Collectively, our journalists put out more than 1,000 stories and 250 photographs including graphics every day to feed the appetite of the diverse subscribers, who include the mainstream media, the specialized presses, research groups, companies, and government and non-governmental organizations.

General Access

Add On Customer Packages

The Press Trust Of India Ltd.

PTI building 4, Parliament Street, New Delhi-110 001

© PTI 2021, All Right Reserved

Designed by: 4c Plus